Clinical Trials Browser

Lymphoma, T-Cell, Peripheral × tislelizumab × 90 days × Clear all

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell